Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals, Inc.

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Madrigal Pharmaceuticals today and set a price target of $709.00. Devarako...

Madrigal Pharmaceuticals (MDGL) Gets a Buy from Truist Financial

In a report released today, Ashwani Verma from UBS maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $669.00. According t...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MDGL	$508.30	-0.34%	63.06K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MDGL	$508.30	-0.3%	63.06K
3
4
5
6

MDGL

MDGL

Get Madrigal Pharmaceuticals, Inc. Data in Excel

Get Madrigal Pharmaceuticals, Inc. Data in Excel